Journal of Medicine and Life Science

Institute for Medical Science (제주대학교 의과학연구소)
권호 표지
DOI QR코드

DOI QR Code

The relationship between glucagon levels and cardiovascular risk in patients with type 2 diabetes

제2형 당뇨병환자에서 혈중 글루카곤 농도와 심혈관 질환 위험도의 관계

  • Jeong, Wooseok (Department of Internal Medicine, Jeju National University School of Medicine) ;
  • Moon, Jaecheol (Department of Internal Medicine, Jeju National University Hospital) ;
  • Yoo, Soyeon (Department of Internal Medicine, Jeju National University School of Medicine)
  • 정우석 (제주대학교 의학전문대학원 내과학교실) ;
  • 문재철 (제주대학교병원 내과) ;
  • 유소연 (제주대학교 의학전문대학원 내과학교실)
  • Received : 2020.07.14
  • Accepted : 2020.08.01
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Glucagon regulates glucose and fat metabolism as well as being involved in the production of ketone bodies. The new antidiabetic drug, a sodium-glucose co-transporter-2 inhibitor, increases glucagon, and reduces the risk of cardiovascular death and hospitalization due to heart failure. The presence of metabolic syndrome is an important risk factor for cardiovascular diseases(CVD) in type 2 diabetes(T2DM) patients. We, thus, investigated the association between glucagon levels and metabolic syndrome in T2DM patients. This cross-sectional study involved 317 T2DM patients. Fasting and postprandial (30 min after ingestion of a standard mixed meal) glucagon levels were measured. Metabolic syndrome was defined according to the criteria of the International Diabetes Federation. A multiple regression logistic analysis was employed for statistical evaluation. A total of 219 (69%) subjects had metabolic syndrome. The fasting and postprandial glucagon levels did not differ between the group with metabolic syndrome and the group without. Postprandial glucagon levels increased significantly with the increase in the number of metabolic syndrome components, but the fasting levels did not. However, a hierarchical logistic regression analysis revealed that the postprandial glucagon levels did not contribute significantly to metabolic syndrome even after adjusting for other covariates. Fasting and postprandial glucagon levels are not associated with metabolic syndrome in T2DM patients. However, further studies are needed to investigate the relationship between glucagon and cardiovascular risk in patients with T2DM.

Keywords

References

  1. Sutherland EW, De Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem 1948;175:663-74. https://doi.org/10.1016/S0021-9258(18)57183-0
  2. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116. https://doi.org/10.1210/er.2006-0007
  3. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970;49:837-48. https://doi.org/10.1172/JCI106297
  4. Menge BA, Gruber L, Jorgensen SM, Deacon CF, Schmidt WE, Veldhuis JD, et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes 2011;60:2160-8. https://doi.org/10.2337/db11-0251
  5. Ahren B. Glucagon--Early breakthroughs and recent discoveries. Peptides 2015;67:74-81. https://doi.org/10.1016/j.peptides.2015.03.011
  6. Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol 2016;15:123. https://doi.org/10.1186/s12933-016-0440-3
  7. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9. https://doi.org/10.1016/S0140-6736(18)32590-X
  8. Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab 2017;43:512-20. https://doi.org/10.1016/j.diabet.2017.04.002
  9. Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen N, et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc 2017;6(3).
  10. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32. https://doi.org/10.1016/j.jacc.2010.05.034
  11. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona diabetes complications study. Diabet Med 2004;21:52-8. https://doi.org/10.1046/j.1464-5491.2003.01068.x
  12. Nishimura E, Abrahamsen N, Hansen L, Lundgren K, Madsen O. Regulation of glucagon receptor expression. Acta Physiol Scand 1996;157:329-32. https://doi.org/10.1046/j.1365-201x.1996.35258000.x
  13. Manchester JH, Parmley WW, Matloff JM, Leidtke AJ, Laraia PJ, Herman MV, et al. Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and in dog. Circulation 1970;41:579-88. https://doi.org/10.1161/01.CIR.41.4.579
  14. Love JN, Leasure JA, Mundt DJ, Janz TG. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol 1992;30:399-412. https://doi.org/10.3109/15563659209021555
  15. Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med 1968;279:12-7. https://doi.org/10.1056/NEJM196807042790103
  16. Lvoff R, Wilcken DE. Glucagon in heart failure and in cardiogenic shock: Experience in 50 patients. Circulation 1972;45:534-42. https://doi.org/10.1161/01.CIR.45.3.534
  17. Arstila M, Iisalo E, Kallio V, Nousiainen R, Viljanen M. The effect of a long-acting glucagon preparation on endocrine and metabolic responses in acute myocardial infarction. Acta Medica Scandinavica 1974;196:423-30. https://doi.org/10.1111/j.0954-6820.1974.tb01034.x
  18. Nord HJ, Fontanes AL, Williams Jr JF. Treatment of congestive heart failure with glucagon. Ann Intern Med 1970;72:649-53. https://doi.org/10.7326/0003-4819-72-5-649
  19. McMurray JJ, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. https://doi.org/10.1056/NEJMoa1911303
  20. Lam CS, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects. J Am Heart Assoc 2019;8:e013389.
  21. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512. https://doi.org/10.1038/nm.3828
  22. Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol 2016;15:123. https://doi.org/10.1186/s12933-016-0440-3
  23. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care 2016;39:1108-14. https://doi.org/10.2337/dc16-0330